Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Smolle, MA; Prinz, F; Calin, GA; Pichler, M.
Current concepts of non-coding RNA regulation of immune checkpoints in cancer.
Mol Aspects Med. 2019; 70:117-126
Doi: 10.1016/j.mam.2019.09.007
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Pichler Martin
-
Smolle Maria Anna
- Co-Autor*innen der Med Uni Graz
-
Prinz Felix
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
The discovery of immune checkpoint molecules as important regulators of immune responses in healthy individuals as well as immune escape of malignant tumours has led to profound changes in understanding, research and treatment of human cancer. Especially the introduction of immune checkpoint inhibitors in cancer therapy has set anti-cancer therapy on a novel level. With increasing experience of approved CTLA-4 and PD1/PD-L1 inhibitors and the evolution of novel immune checkpoint molecules from pre-clinical models to clinical trials, mechanisms of the regulation of these immune system guiding factors, are of paramount importance to overcome mechanisms of resistance. Non-protein coding RNAs (i.e. non-coding RNAs) such as short microRNAs and long non-coding RNAs are involved in regulating of various cellular processes and have attracted attention of cancer researchers and immunologists over the last years. In the present review, interactions between non coding RNAs and immune checkpoint molecules, within the framework of human cancer, will be discussed and current and developing concepts between the immunological and non-coding RNA world, will be elucidated.
Copyright © 2019 Elsevier Ltd. All rights reserved.
- Find related publications in this database (Keywords)
-
Immune checkpoint molecule
-
Non-coding RNA
-
Cancer